HD-OPM Archive
Topics › Guidelines, policy & public health

2026 ACC/AHA lipid guideline keeps LDL targets and adds Lp(a), apoB and CAC testing

Louis Nervegna · Mar 13, 2026 · ♥ 29 reactions · 10 comments · original Facebook post
Guidelines, policy & public healthLDL, ApoB & lipid panelLp(a)
AI summary & key facts

Louis summarizes the updated lipid guideline: LDL goals stay risk-scaled, with early prevention emphasis and consideration of Lp(a), apoB and CAC testing to guide intensity.

Today, the American Heart Association (AHA) and the American College of Cardiology (ACC) issued updated guidance for managing lipids and cholesterol.

American Heart AssociationACC/American Heart Association Issue Updated Guideline for Managing Lipids, CholesterolEmbargoed until 1 p.m. CT/2 p.m. ET, Friday, March 13, 2026 WASHINGTON and DALLAS, March 13, 2026 — The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated guideline ...newsroom.heart.org Paper · JACC · 2026Clinical Guidelines as a Continuous Work in Progress: Moving at the Speed of Sciencejacc.org
  1. The LDL targets from past guidelines remain essentially the same, and still scale with level risk. A specific target is set for “very high risk”:

“To prevent a first heart attack or stroke, the LDL-C goal should be less than 100 mg/dL for those at borderline or intermediate risk and less than 70 mg/dL in those at high risk. For individuals with ASCVD who are at very high risk of ASCVD events, the LDL-C goal should be less than 55 mg/dL for secondary prevention of cardiac events.”

  1. There is increased emphasis on adopting healthy lifestyle changes and prevention strategies (including medication) early in life before damage is done:

“A major focus of the guideline is earlier intervention through healthy lifestyle changes, such as maintaining a healthy weight, engaging in regular physical activity, avoiding tobacco products, prioritizing healthy sleep habits and taking cholesterol-lowering medication when recommended by a health care professional. In addition, the guideline reinforces lower LDL-C goals and percent reduction based on risk to reduce lifetime exposure to unhealthy lipids and the risk of heart attack and stroke.”

  1. They now recommend additional testing, such as Lp(a), ApoB, and CAC scans:

“The new guideline recommends the consideration of additional tests, when appropriate, to improve cardiovascular risk assessment and assess if more intensified LDL-C lowering and management of other risk factors is needed. These include:

Selective use of a non-contrast coronary artery calcium (CAC) scan: This can be used to check for early or subclinical calcium and plaque buildup in the walls of the heart’s arteries when there remains uncertainty about a person’s true risk. It is recommended for men age 40 and older and women age 45 and older with borderline or intermediate 10-year risk of heart attack or stroke if knowing CAC will help with the decision to prescribe a statin or not. Having any amount of coronary artery calcium supports an LDL-C goal of less than 100 mg/dL—with lower LDL-C target levels with higher amounts of calcium.

Lipoprotein (a): Lp(a) should be measured at least once in adulthood. Lp(a) levels are largely genetically determined and remain relatively stable over a lifetime. High Lp(a) (125 nmol/L or greater or 50 mg/dL or greater) is associated with about a 1.4-fold increased long-term risk of heart attack or stroke. An Lp(a) of 250 nmol/L is associated with at least a two-fold increased long-term risk of heart attack or stroke. Lifestyle changes minimally affect Lp(a) levels, so repeat testing is generally not needed.

Apolipoprotein B: Measuring apoB may be used to assess any residual ASCVD risk and guide treatment among people with cardiovascular-kidney-metabolic syndrome, Type 2 diabetes, high triglycerides or known cardiovascular disease who have reached their LDL-C and non-HDL-C goals. ApoB may be a more accurate risk marker than LDL-C in these groups of people.”

  1. For assessing risk for primary prevention, they recommend using the new AHA risk calculator based on the PREVENT equations:

↪ AHA PREVENT calculator replaces Pooled Cohort Equations for ages 30-79

(They note that the old calculator likely overestimated risk, meaning more people were placed on cholesterol medication than really necessary.)

“New to the dyslipidemia guideline is the use of a newer, more contemporary cardiovascular disease risk calculator—Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) — now recommended for primary prevention of ASCVD. The PREVENT-ASCVD equations are designed for adults ages 30-79 years without known ASCVD or subclinical atherosclerosis and with LDL-C 70–189 mg/dL to estimate 10- and 30- year risk of heart attack or stroke and guide lipid-lowering therapy. Lipid-lowering therapy includes statins and other newer treatments in addition to lifestyle management, all aimed at lowering lipid levels.

Older risk scores like the Pooled Cohort Equations overestimated the 10-year risk of a heart attack and stroke by 40%-50%, Blumenthal explained. The updated risk categories from the PREVENT-ASCVD equations classify 10-year ASCVD risk as low (<3%), borderline (3% to <5%), intermediate (5% to <10%), and high (10% or higher). These risk categories guide treatment decisions, including whether to initiate statin therapy and the recommended intensity of lipid-lowering therapy.”

  1. They recommend personalizing results of the new AHA risk calculator, by assessing each person’s individual “risk enhancers”:

“ “With this new assessment tool, we can better estimate cardiovascular risk using health information already obtained during an annual physical—cholesterol, blood pressure readings and other personal information such as age and health habits—and then further personalize the risk score for each individual by looking at ‘risk enhancers,’ which can help guide the need for lipid-lowering therapy,” Blumenthal said.

Such risk enhancers include a family history of heart disease; chronic inflammatory conditions (e.g., lupus or rheumatoid arthritis); cardiometabolic conditions such as overweight/obesity, diabetes or chronic kidney disease; higher-risk ancestry such as South Asian or Filipino ancestry or other ancestral groups with an enhanced risk for developing atherosclerosis; and reproductive risk markers, including early menopause, preeclampsia and gestational diabetes. Additional markers, including lipoprotein(a) [Lp(a)], apolipoprotein B (apoB), high-sensitivity C-reactive protein (hsCRP) and elevated triglycerides, can be used to refine an individual’s ASCVD risk.

“Having healthy LDL-cholesterol levels or high-density lipoprotein-cholesterol (HDL-C), traditionally thought of as ‘good’ cholesterol, isn’t necessarily a ‘get out of jail free’ card,” Blumenthal said. “Measuring other biomarkers can give a more complete picture of someone’s cardiovascular risk and help inform decisions about whether lipid-lowering therapy is needed sooner rather than later or if more intensive therapy is warranted.” “

#guidelinesHD #ahaHD #accHD #calculatorHD #lpaHD #apobHD #cacHD #ldlHD #preventHD

Research cited

← newer: Life's Essential 8 adherence for 10 years linked to 66% loweolder: Thickened Achilles tendon predicts MACE after stenting: 28.4 →